almost 5% (free cash flow) of billions is not all that bad when you consider the amount of time and money Roche has invested to bring this compound to market and then the cost to market and sell the product. All of those activities are high cost, I am sure Roche has invested well over $1BB already. This was an old deal, made before the technology was proven, I am sure more recent deal terms were much improved and future deals will be very significant and hopefully prevent any further dilution if IMGN remains a public company. Roche got the job done, so let's be grateful for their accomplishment and the revenue. Now we need something new, something next and ASAP would be good.